Abeona Therapeutics Inc (NASDAQ:ABEO – Get Rating) – Analysts at Cantor Fitzgerald raised their FY2022 earnings per share (EPS) estimates for shares of Abeona Therapeutics in a research note issued on Wednesday, May 18th. Cantor Fitzgerald analyst K. Kluska now expects that the biopharmaceutical company will post earnings per share of ($0.43) for the year, up from their previous forecast of ($0.44).
A number of other research analysts have also issued reports on the stock. Zacks Investment Research upgraded shares of Abeona Therapeutics from a “hold” rating to a “buy” rating and set a $0.25 target price on the stock in a research note on Tuesday, April 5th. StockNews.com began coverage on shares of Abeona Therapeutics in a research note on Saturday. They issued a “hold” rating on the stock. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat.com, Abeona Therapeutics currently has an average rating of “Buy” and an average target price of $1.75.
Abeona Therapeutics (NASDAQ:ABEO – Get Rating) last announced its quarterly earnings results on Friday, May 13th. The biopharmaceutical company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.04).
A number of institutional investors and hedge funds have recently bought and sold shares of the business. GSA Capital Partners LLP acquired a new position in Abeona Therapeutics during the third quarter valued at approximately $37,000. BlackRock Inc. grew its holdings in Abeona Therapeutics by 4.7% during the first quarter. BlackRock Inc. now owns 1,694,624 shares of the biopharmaceutical company’s stock valued at $534,000 after purchasing an additional 76,694 shares during the period. Citigroup Inc. bought a new position in Abeona Therapeutics in the first quarter valued at approximately $27,000. Worth Venture Partners LLC lifted its stake in Abeona Therapeutics by 9.5% in the first quarter. Worth Venture Partners LLC now owns 1,244,774 shares of the biopharmaceutical company’s stock valued at $392,000 after buying an additional 107,500 shares in the last quarter. Finally, Millennium Management LLC lifted its stake in Abeona Therapeutics by 20.3% in the fourth quarter. Millennium Management LLC now owns 825,996 shares of the biopharmaceutical company’s stock valued at $278,000 after buying an additional 139,259 shares in the last quarter. Hedge funds and other institutional investors own 27.81% of the company’s stock.
About Abeona Therapeutics (Get Rating)
Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.
- Get a free copy of the StockNews.com research report on Abeona Therapeutics (ABEO)
- MarketBeat: Week in Review 5/16 – 5/20
- 3 Retailers That Defied First Quarter Headwinds
- Rapid7: Could Be Profitable in FY 2022 Despite Bear Market
- Will John Deere’s Earnings Help to Calm the Markets?
- Lowe’s Companies Has Not Bottomed
Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.